Citations 2
Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study
Zarif, Talal El, Alaiwi, Sarah Abou, Gariazzo, Eleonora, Santo, Valentina, Garbo, Edoardo , Aldea, Mihaela, Pannu, Sagal, Semaan, Karl , Chehab, Omar , Hoballah, Malak, Y, Gao , Meyers, Daniel, Stukalin, Igor , Li, MT, Jones, Nicholas, Shapira, Ronnie, Vasbinder, Alexi, Hayek, Salim S. , Eid, Marc , Freeman, Dory, Parikh, Kaushal, Desai, Aakash, Cd, Smith, El-Am, Edward, Foderaro, Simone , Baena-, Javier, Cortellini, Alessio, Pinato, David J, Korolewicz, James , Kim, Chul , Sackstein, Paul, Denu, Ryan A, Abdel-wahab, Noha, Neilan, Tomas G. , Lima, Joao A C, Florez, Narjust, Janne, Pasi, Pecci, Federica , Choueiri, Toni K, Kwan, Jennifer M. , Naqash, Abdul Rafeh , Desai, Aakash , El Zarif, Talal , Garbo, Edoardo , Semaan, Karl , Grynberg, Shirly , Bou Farhat, Elias , Eid, Marc , Saad, Eddy , Desai, Aakash P , Kim, Chul , Jänne, Pasi A , Naqash, Abdul Rafeh , Hayek, Salim , Alaiwi, Sarah Abou , Nassar, Amin H. , Gariazzo, Eleonora , Santo, Valentina , Aldea, Mihaela , Paoloni, Francesco , Chehab, Omar , Navani, Vishal , Meyers, Daniel E. , Mittra, Arjun , Grynberg, Shirly , Vasbinder, Alexi L. , Farhat, Elias Bou , Saad, Eddy , Freeman, Dory , El‐Am, Edward , Nana, Frank Aboubakar , Baena, Javier, Herrera, Mercedes, Cortellini, Alessio , Pinato, David J. , Sackstein, Paul , Denu, Ryan , Macaron, Walid , Abdel‐Wahab, Noha , Lima, João A.C. , Florez, Narjust , Jänne, Pasi A. , Ricciuti, Biagio , Choueiri, Toni K.
The Oncologist | July 25, 2026 | Volume: 31 | Issue: 9 | Pages: No page available
Abstract Background There is limited data on immune checkpoint inhibitor (ICI) use in patients with non-small cell lung cancer (NSCLC) and known pericardial effusions. Methods This international multi-center observational retrospective study included patients with advanced NSCLC with or without pericardial effusions receiving ICIs. Immune-related adverse events (irAEs) were graded per CTCAE v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Cox proportional hazards multivariable models assessed the association between survival outcomes and clinicopathologic variables, and an inverse probability of treatment weighting (IPTW) model compared outcomes between the two groups. Results A total of 1248 patients with advanced NSCLC treated with ICIs across 13 institutions were included. Of these, 85 patients (6.8%) had pre-existing pericardial effusions. Compared to controls, patients with pericardial effusions were younger (median age 63 vs 67 years, P = .007), diagnosed more frequently with PD-L1 positive tumors (96% vs 76%, P < .001), and had a higher median number of baseline metastatic sites (3 vs 1, P < .001). IrAEs were similar between both groups (42% vs 38%), and no cardiac irAEs occurred in patients with pericardial effusions. PFS (median 5.6 vs 4.6 months, P = .3) and OS (median 10.2 vs 14.7 months, P = .50) were not statistically different between patients with pericardial effusions and the controls, respectively. In both multivariable and IPTW models, pericardial effusions were not associated with PFS or OS. Conclusions Among patients with NSCLC and pre-existing pericardial effusions, ICIs demonstrate meaningful clinical benefit similar to those without effusions, with no new cardiac or severe toxicities.
Abstract 4371215: ANGPTL3 Targeting Monoclonal Antibodies Lead to Robust Reductions in LDL-C, Triglycerides, ApoB, and Non-HDL-C in Dyslipidemic Patients: A Meta-Analysis of 5 Randomized Controlled Trials
Daid, Simranpreet Singh, Sharma, Arundhati , Pannu, Sagal, Asnani, Heena , Bhanushali, Karan B. , Choudhary, Khushal, Sharma, Anubhuti , Sharma, Saurabh
Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available
10.1161/circ.152.suppl_3.4371215
Introduction: Dyslipidemia remains a major driver of cardiovascular disease. Monoclonal antibodies (mAb) that block angiopoietin-like protein 3 (ANGPTL3) lower atherogenic lipids by a mechanism distinct from statins. Earlier evidence centred on the Evinacumab. A new trial now evaluate the investigational antibody SHR-1918. Hypothesis: We hypothesized that treatment with ANGPTL3 mAbs whether evinacumab or SHR-1918 would significantly improve lipid parameters compared to placebo without increasing adverse events. Aims: To Quantify the pooled effect of ANGPTL3 mAbs on low-density lipoprotein cholesterol (LDL-C), Triglycerides, apolipoprotein B (ApoB) and non-high-density lipoprotein cholesterol (non-HDL-C) and Compare efficacy and safety between Evinacumab and SHR-1918 subgroups. Methods: A systematic search of Pubmed, Google Scholar MEDLINE, Embase, and ClinicalTrials.gov untill 1 April 2025 was done and relevant randomised controlled trials (RCT's) comparing ANGPTL3 mAbs with placebo in dyslipidaemic patients were included. Data was extracted on spreadsheet and Data analysis was done in RevMan 5.4. Results: 5 RCT's comprising of 603 patients met inclusion criteria. The pooled analysis showed marked reductions in atherogenic lipids with ANGPTL3 monoclonal antibodies versus placebo, including low-density lipoprotein cholesterol (SMD = –2.73, 95 % CI –4.16 to –1.31, P < 0.001), triglycerides (SMD = –3.54, 95 % CI –4.71 to –2.37, P < 0.001), apolipoprotein B (SMD = –1.98, 95 % CI –2.97 to –1.00, P < 0.001) and non-HDL-C (SMD = –2.89, 95 % CI –4.00 to –1.78, P < 0.001). Sub-group analyses demonstrated directionally consistent lipid lowering for both evinacumab and the newer agent SHR-1918. Adverse-event due to treatment evaluation revealed no significant increase in Adverse events due to treatment (RR = 1.05, 95 % CI 0.87 to 1.27, P = 0.63) or serious events (RR = 1.37, 95 % CI 0.54 to 3.44, P = 0.49), indicating good overall tolerability. Conclusion: monoclonal antibodies targeting ANGPTL3 encompassing both evinacumab and the newer agent SHR-1918 consistently reduced LDL-C, triglycerides, and related lipid markers with a favourable tolerability profile. Further large, long-term studies are needed to fully establish their safety, clinical effectiveness, and potential to improve cardiovascular outcomes.